BioTuesdays

Tag - CNCE

Concert starts multiple dose trial with CF drug

Concert Pharmaceuticals (NASDAQ:CNCE), which is modifying known drugs with its deuterium technology, last week initiated a multiple ascending dose Phase 1 trial with healthy volunteers of its next generation drug for...

Subscribe

Sign up to our weekly BioTuesdays newsletter.